New PET radiopharmaceuticals beyond FDG for brain tumor imaging

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 2, 2012, Pages 173-190

  Gulyas B ^a   Halldin, C ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biological markers; Brain neoplasms; Positron emission tomography, fluorodeoxyglucose F18; Radioligand assay

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3 METHYLSPIPERONE C 11; 3' FLUOROTHYMIDINE F 18; 6 FLUORODOPA F 18; ACETIC ACID C 11; AMINO ACID DERIVATIVE; AMMONIA N 13; BENZODIAZEPINE RECEPTOR; BIOLOGICAL MARKER; CETUXIMAB; CETUXIMAB CU 64; CHOLINE C 11; CHOLINE F 18; COPPER 64; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORINE 18; FLUORO ALPHA METHYLTYROSINE; FLUOROETHYLTYROSINE F 18; GALLIUM 68; METHIONINE C 11; NEW DRUG; NITROGEN 15; NUCLEOSIDE; OXYGEN 15; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; YTTRIUM 86;

AEROBIC METABOLISM; ANGIOGENESIS; BLOOD BRAIN BARRIER; BLOOD FLOW; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FATTY ACID METABOLISM; HUMAN; HYPOXIA; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY;

BRAIN NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84864386757     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (297)

1. Warburg O, Posener K, Negelein E. Ueber den Stoffwechsel der Tumoren [German]. Biochemische Zeitschrift 1924;152:319-44.
2. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916. (Pubitemid 8098854)
3. Tewson TJ, Welch MJ, Raichle ME. [18F]-labeled 3-deoxy-3-fluoro-D- glucose: synthesis and preliminary biodistribution data. J Nucl Med 1978;19:1339-45. (Pubitemid 9098941)
4. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371-388. (Pubitemid 10203423)
5. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH et al. Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-9. (Pubitemid 13218489)
6. Herholz K, Coope D, Jackson A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol 2007;6:711-24. (Pubitemid 47058386)
7. van Waarde A, Elsinga PH. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des 2008;14:3326-39.
8. Caroli P, Nanni C, Rubello D, Alavi A, Fanti S. Non-FDG PET in the practice of oncology. Indian J Cancer 2010;47:120-5.
9. Petrirena GJ, Goldman S, Delattre JY. Advances in PET imaging of brain tumors: a referring physician's perspective. Curr Opin Oncol 2011;23:617-23.
10. Gulyás B, Nyáry I, Borbély K. FDG, MET or CHO? The quest for the optimal PET tracer for glioma imaging continues. Nat Clin Pract Neurol 2008;4:470-1.
11. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:718-79.
12. Biersack HJ, Freeman LM. Clinical nuclear medicine. Berlin: Springer; 2007.
13. Phelps ME, Barrio JR, Huang SC, Keen RE, Chugani H, Mazziotta JC. Criteria for the tracer kinetic measurement of cerebral protein synthesis in humans with positron emission tomography. Ann Neurol 1984; 15 Suppl:S192-202. (Pubitemid 14138684)
14. Vaalburg W, Coenen HH, Crouzel C, Elsinga PH, Långström B, Lemaire C et al. Amino acids for the measurement of protein synthesis in vivo by PET. Int J Rad Appl Instrum B 1992;19:227-237.
15. Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 1993;34:1936-1943. (Pubitemid 23331262)
16. Deng H, Tang X, Wang H, Tang G, Wen F, Shi X et al. S-11C-methyl-L- cysteine: a new amino acid PET tracer for cancer imaging. J Nucl Med 2011;52:287-93.
17. Leung K. p-(2-[18F]Fluoroethyl)-l-phenylalanine. Molecular Imaging and Contrast Agent Database (MICAD) Bethesda (MD): National Center for Biotechnology Information (US); 2004-2011.
18. Wang L, Lieberman BP, Plössl K, Qu W, Kung HF. Synthesis and comparative biological evaluation of L- and D-isomers of 18F-labeled fluoroalkyl phenylalanine derivatives as tumor imaging agents. Nucl Med Biol 2011;38:301-12.
19. Wang L, Qu W, Lieberman BP, Plössl K, Kung HF. Synthesis, uptake mechanism characterization and biological evaluation of (18)F labeled fluoroalkyl phenylalanine analogs as potential PET imaging agents. Nucl Med Biol 2011;38:53-62.
20. Shandal V, Sundaram SK, Chugani DC, Kumar A, Behen ME, Chugani HT. Abnormal Brain Protein Synthesis in Language Areas of Children With Pervasive Developmental Disorder: A L-[1-11C]-Leucine PET Study. J Child Neurol 2011;26:1347-54.
21. Tomasi G, Bertoldo A, Bishu S, Unterman A, Smith CB, Schmidt KC. Voxel-based estimation of kinetic model parameters of the L-[1-(11)C]leucine PET method for determination of regional rates of cerebral protein synthesis: validation and comparison with region-of-interest-based methods. J Cereb Blood Flow Metab 2009;29:1317-31.
22. Syrota A, Duquesnoy N, Paraf A, Kellershohn C. The role of positron emission tomography in the detection of pancreatic disease. Radiology 1982;143:249-53. (Pubitemid 12142209)
23. Bergström M, Collins VP, Ehrin E, Ericson K, Eriksson L, Greitz T et al. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 1983;7:1062-6. (Pubitemid 14246648)
24. Bergström M, Collins VP, Ehrin E, Ericson K, Eriksson L, Greitz T et al. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 1983;7:1062-6. (Pubitemid 14246648)
25. Ericson K, Lilja A, Bergström M, Collins VP, Eriksson L, Ehrin E et al. Positron emission tomography with ([11C]methyl)-L-methionine, [11C]D-glucose, and [68Ga]EDTA in supratentorial tumors. J Comput Assist Tomogr 1985;9:683-9. (Pubitemid 15008674)
26. Lilja A, Bergström K, Hartvig P, Spännare B, Halldin C, Lundqvist H et al. Dynamic study of supratentorial gliomas with L-methyl-11C-methionine and positron emission tomography. AJNR Am J Neuroradiol 1985;6:505-14. (Pubitemid 15070032)
27. Ericson K, von Holst H, Mosskin M, Bergström M, Lindqvist M, Norén G et al. Positron emission tomography of cavernous haemangiomas of the brain. Acta Radiol Diagn (Stockh) 1986;27:379-83. (Pubitemid 17183493)
28. Mosskin M, von Holst H, Bergström M, Collins VP, Eriksson L, Johnström P et al. Positron emission tomography with 11C-methionine and computed tomography of intracranial tumours compared with histopathologic examination of multiple biopsies. Acta Radiol 1987;28:673-81. (Pubitemid 18041770)
29. Bergström M, Muhr C, Lundberg PO, Bergström K, Gee AD, Fasth KJ et al. Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study. J Comput Assist Tomogr 1987;11:815-9. (Pubitemid 17138491)
30. Ericson K, Blomqvist G, Bergström M, Eriksson L, Stone-Elander S. Application of a kinetic model on the methionine accumulation in intracranial tumours studied with positron emission tomography. Acta Radiol 1987;28:505-9. (Pubitemid 18004822)
31. Bergström M, Muhr C, Lundberg PO, Bergström K, Lundqvist H, Antoni G et al. Amino acid distribution and metabolism in pituitary adenomas using positron emission tomography with D-[11C]methionine and L-[11C]methionine. J Comput Assist Tomogr 1987;11:384-9.
32. Bergström M, Ericson K, Hagenfeldt L, Mosskin M, von Holst H, Norén G et al. PET study of methionine accumulation in glioma and normal brain tissue: competition with branched chain amino acids. J Comput Assist Tomogr 1987;11:208-13.
33. Bergström M, Muhr C, Ericson K, Lundqvist H, Lilja A, Eriksson L et al. The normal pituitary examined with positron emission tomography and (methyl-11C)-L-methionine and (methyl-11C)-D-methionine. Neuroradiology 1987;29:221-5. (Pubitemid 17077444)
34. Schober O, Duden C, Meyer GJ, Müller JA, Hundeshagen H. Non selective transport of [11C-methyl]-L-and D-methionine into a malignant glioma. Eur J Nucl Med 1987;13:103-5. (Pubitemid 17091386)
35. Muhr C, Bergström M, Lundberg PO, Hartman M, Bergström K, Pellettieri L et al. Malignant prolactinoma with multiple intracranial metastases studied with positron emission tomography. Neurosurgery 1988;22:374-9. (Pubitemid 18076690)
36. Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins VP, Bergström M et al. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol 1989;30:225-32. (Pubitemid 19152548)
37. Tovi M, Lilja A, Bergström M, Ericsson A, Bergström K, Hartman M. Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography. Acta Radiol 1990;31:417-29.
38. Bergström M, Muhr C, Lundberg PO, Långström B. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 1991;32:610-15.
39. Bergström M, Muhr C, Jossan S, Lilja A, Nyberg G, Långström B. Differentiation of pituitary adenoma and meningioma: visualization with positron emission tomography and [11C]-L-deprenyl. Neurosurgery 1992;30:855-61.
40. Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Långström B et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer 2001;92:1541-9. (Pubitemid 32947840)
41. Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M et al. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 2004;101:476-83. (Pubitemid 39100725)
42. Kato T, Shinoda J, Oka N, Miwa K, Nakayama N, Yano H et al. Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity. AJNR Am J Neuroradiol 2008;29:1867-71.
43. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008;49:694-699. (Pubitemid 351717532)
44. Kawai N, Miyake K, Yamamoto Y, Nishiyama Y, Maeda Y, Kageji T et al. Use of 11C-methionine positron emission tomography in basal germinoma: assessment of treatment response and residual tumor. Childs Nerv Syst 2009;25:845-53.
45. Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med 2009;50:1962-8.
46. Galldiks N, Ullrich R, Schroeter M, Fink GR, Jacobs AH, Kracht LW. Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging 2010;37:84-892.
47. Galldiks N, Kracht LW, Berthold F, Miletic H, Klein JC, Herholz K et al. [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol 2010;96:231-9.
48. Kim YH, Oh SW, Lim YJ, Park CK, Lee SH, Kang KW et al. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg 2010;112:758-65.
49. Phi JH, Paeng JC, Lee HS, Wang KC, Cho BK, Lee JY et al. Evaluation of focal cortical dysplasia and mixed neuronal and glial tumors in pediatric epilepsy patients using 18F-FDG and 11C-methionine pet. J Nucl Med 2010;51:728-34.
50. Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R, Tamiya T. Correlation of L-methy 1-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol 2010;99:217-25.
51. Yamane T, Sakamoto S, Senda M. Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm. Eur J Nucl Med Mol Imaging 2010;37:685-90.
52. Rottenburger C, Hentschel M, Kelly T, Trippel M, Brink I, Reithmeier T et al. Comparison of C-11 methionine and C-11 choline for PET imaging of brain metastases: a prospective pilot study. Clin Nucl Med 2011;36:639-42.
53. Petrirena GJ, Goldman S, Delattre JY. Advances in PET imaging of brain tumors: a referring physician's perspective. Curr Opin Oncol 2011;23:617-23.
54. Kawase Y, Yamamoto Y, Kameyama R, Kawai N, Kudomi N, Nishiyama Y. Comparison of (11)C-Methionine PET and (18) F-FDG PET in Patients with Primary Central Nervous System Lymphoma. Mol Imaging Biol 2011;13:1284-9.
55. Arita H, Kinoshita M, Okita Y, Hirayama R, Watabe T, Ishohashi K et al. Clinical characteristics of meningiomas assessed by (11) C-methionine and (18)F-fluorodeoxyglucose positron-emission tomography. J Neurooncol 2012;107:379-86.
56. Kinoshita M, Goto T, Arita H, Okita Y, Isohashi K, Kagawa N et al. Imaging (18)F-fluorodeoxy glucose/(11)C-methionine uptake decoupling for identification of tumor cell infiltration in peritumoral brain edema. J Neurooncol 2012;106:417-25.
57. Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M et al. J Nucl Med 1999;40:205-12.
58. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C] methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27:542-9. (Pubitemid 30262620)
59. Weber DC, Zilli T, Buchegger F, Casanova N, Haller G, Rouzaud M et al. [(18)F]Fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol 2008;24:44.
60. Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H et al. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol 2009:36:779-87.
61. Vees H, Senthamizhchelvan S, Miralbell R, Weber DC, Ratib O, Zaidi H. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging 2009;36:182-93.
62. Lau EW, Drummond KJ, Ware RE, Drummond E, Hogg A, Ryan G et al. Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J. Clin Neurosci 2010;17:43-9.
63. Langen KJ, Floeth FW, Stoffels G, Hamacher K, Coenen HH, Pauleit D. [Improved diagnostics of cerebral gliomas using FET PET]. Z Med Phys 2007;17:237-41.
64. Pöpperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 2007;34:1933-42. (Pubitemid 350212135)
65. Floeth FW, Sabel M, Stoffels G, Pauleit D, Hamacher K, Steiger HJ et al. Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions. J Nucl Med 2008;49:730-7. (Pubitemid 351717537)
66. Stadibauer A, Prante O, Nimsky C, Salomonowitz E, Buchfelder M, Kuwert T et al. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med 2008;49:721-9. (Pubitemid 351717536)
67. Stadlbauer A, Pölking E, Prante O, Nimsky C, Buchfelder M, Kuwert T et al. Detection of tumour invasion into the pyramidal tract in glioma patients with sensorimotor deficits by correlation of (18)F-fluoroethyl-L: -tyrosine PET and magnetic resonance diffusion tensor imaging. Acta Neurochir (Wien) 2009;151:1061-9.
68. Thiele F, Ehmer J, Piroth MD, Eble MJ, Coenen HH, Kaiser HJ et al. The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. Phys Med Biol 2009;54:5525-39.
69. Spaeth N, Wyss MT, Pahnke J, Biollaz G, Lutz A, Goepfert K et al. Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L: -tyrosine and 18F-fluoro-2- deoxyglucose in F98 gliomas in the rat. Eur J Nucl Med Mol Imaging 2006;33:673-82. (Pubitemid 43846758)
70. Piroth MD, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C et al. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme - a dosimetric comparison. Radiat Oncol 2009;4:57.
71. Willemsen AT, van Waarde A, Paans AM, Pruim J, Luurtsema G, Go KG et al. In vivo protein synthesis rate determination in primary or recurrent brain tumors using L-[1-11C]-tyrosine and PET. J Nucl Med 1995;36:411-9.
72. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C] methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27:542-9. (Pubitemid 30262620)
73. Messing-Jünger AM, Floeth FW, Pauleit D, Reifenberger G, Willing R, Gärtner J et al. Multimodal target point assessment for stereotactic biopsy in children with diffuse bithalamic astrocytomas. Childs Nerv Syst 2002;18:445-9. (Pubitemid 36013690)
74. Rachinger W, Goetz C, Pöpperl G, Gildehaus FJ, Kreth FW, Holtmannspötter M et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005;57:505-11. (Pubitemid 41254459)
75. Weber DC, Zilli T, Buchegger F, Casanova N, Haller G, Rouzaud M et al. [(18)F]Fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol 2008;3:44.
76. Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med 2011;36:841-7.
77. Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011;80:176-84.
78. Plotkin M, Blechschmidt C, Auf G, Nyuyki F, Geworski L, Denecke T, Brenner et al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur Radiol 2010;20:2496-502.
79. Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011;80:176-84.
80. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F et al. An Interindividual Comparison of O-(2-[(18)F] Fluoroethyl)-L-Tyrosine (FET)- and L-[Methyl-(11)C]Methionine (MET)-PET in Patients With Brain Gliomas and Metastases. Int J Radiat Oncol Biol Phys 2011;81:1049-58.
81. Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N et al. Prognostic impact of postoperative, pre-irradiation (18) F-fluoroethyl-1- tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol 2011;99:218-24.
82. Willemsen AT, van Waarde A, Paans AM, Pruim J, Luurtsema G, Go KG et al. In vivo protein synthesis rate determination in primary or recurrent brain tumors using L-[1-11C]-tyrosine and PET. J Nucl Med 1995;36:411-9.
83. Fedorova OS, Kuznetsova OF, Shatik SV, Stepanova MA, Belokon' IuN, Maleev VI et al. [(18)F-labeled tyrosine derivatives: synthesis and experimental studies on accumulation in tumors and abscesses]. Bioorg Khim 2009;35:334-43.
84. Burchardt C, Riss PJ, Zoller F, Maschauer S, Prante O, Kuwert T et al. [(68)Ga]Ga-DO(2)A-(OBu-l-tyr)(2): synthesis, (68) Ga-radiolabeling and in vitro studies of a novel (68)Ga-DO(2) A-tyrosine conjugate as potential tumor tracer for PET. Bioorg Med Chem Lett 2009;19:3498-501.
85. Krasikova RN, Kuznetsova OF, Fedorova OS, Belokon YN, Maleev VI, Mu L et al. 4-[18F]fluoroglutamic acid (BAY 85-8050), a new amino acid radiotracer for PET imaging of tumors: synthesis and in vitro characterization. J Med Chem 2011;54:406-10.
86. 11C]methyl-L-tryptophan on PET in low-grade brain tumors. J Neurooncol 2011;102:409-15.
87. Benouaich-Amiel A, Lubrano V, Tafani M, Uro-coste E, Gantet P, Sol JC et al. Evaluation of O-(2-[18F]-Fluoroethyl)-L-Tyrosine in the Diagnosis of Glioblastoma. Arch Neurol 2010;67:370-2.
88. Langen KJ, Jarosch M, Hamacher K, Mühlensiepen H, Weber F, Floeth F et al. Imaging of gliomas with Cis-4-[18F]fluoro-L-proline. Nucl Med Biol 2004;31:67-75.
89. Bergmann R, Pietzsch J, Fuechtner F, Pawelke B, Beuthien-Baumann B, Johannsen B et al. 3-O-methyl-6-18F-fluoro-L-dopa, a new tumor imaging agent: investigation of transport mechanism in vitro. J Nucl Med 2004;45:2116-2122. (Pubitemid 47611644)
90. Beuthien-Baumann B. Radiation treatment planning in brain tumours: potential impact of 3-O-methyl-6-[(18)F]fluoro-L-DOPA and PET Nuklearmedizin 2008;47:200-4.
91. Alheit H, Oehme L, Winkler C, Füchtner F, Hoepping A, Grabowski J et al. Radiation treatment planning in brain tumours: potential impact of 3-O-methyl-6-[(18)F]fluoro-L-DOPA and PET. Nuklearmedizin 2008;47:200-4.
92. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med 2010;51:1532-8.
93. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM et al. Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nat Med 1998;4:1334-6. (Pubitemid 28512118)
94. Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, Armstrong D et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3-fluoro-3-deoxythymidine and 3-azido-3-deoxythymidine. Antimicrob Agents Chemother 1992;36:808-18.
95. Toyohara J, Waki A, Takamatsu S, Yonekura Y, Magata Y, Fujibayashi Y. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002;29:281-7. (Pubitemid 34258548)
96. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7. (Pubitemid 34988769)
97. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-23. (Pubitemid 35340704)
98. Wagner M, Seitz U, Buck A, Neumaier B, Schultheiss S, Bangerter M et al. 3-[18F]fluoro-3-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003;63:2681-7. (Pubitemid 36605213)
99. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003;44:2027-32. (Pubitemid 40022149)
100. Lu L, Samuelsson L, Bergström M, Sato K, Fasth KJ, Långström B. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. J Nucl Med 2002;43:1688-98. (Pubitemid 35424996)
101. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q et al. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8. (Pubitemid 36793068)
102. van Waarde A, Cobben DC, Suurmeijer AJ, Maas B, Vaalburg W, de Vries EF et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004;45:695-700. (Pubitemid 47618601)
103. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-23. (Pubitemid 35340704)
104. Buck AK, Schirrmeister H, Hetzel M, Von Der Heide M, Halter G, Glatting G et al. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-4. (Pubitemid 34651372)
105. Cobben DC, Jager PL, Elsinga PH, Maas B, Suurmeijer AJ, Hoekstra HJ. 3-18F-fluoro-3-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? J Nucl Med 2003;44:1927-32. (Pubitemid 40022138)
106. Francis DL, Visvikis D, Costa DC, Arulampalam TH, Townsend C, Luthra SK et al. Potential impact of [18F]3-deoxy-3'fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003;30:988-94. (Pubitemid 37086941)
107. Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003;52:1602-6. (Pubitemid 37363445)
108. Dittmann H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003;30:1407-12. (Pubitemid 37247960)
109. Buchmann I, Neumaier B, Schreckenberger M, Reske S. [18F]3′-deoxy- 3′-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations-a pilot study. Cancer Biother Radiopharm 2004;19:436-42. (Pubitemid 39294750)
110. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005;46:274-82. (Pubitemid 43073435)
111. Herrmann K, Wieder HA, Buck AK, Schöffel M, Krause BJ, Fend F et al. Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine- positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 2007;13:3552-8. (Pubitemid 46955115)
112. Yamamoto Y, Nishiyama Y, Kimura N, Ishikawa S, Okuda M, Bandoh S et al. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2008;35:236-45.
113. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E et al. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 2010;51:340-6.
114. Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, Graf N et al. A Pilot Study to Evaluate 3′-Deoxy-3′-18F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma. J Nucl Med 2011;52:1898-902.
115. Herrmann K, Buck AK, Schuster T, Junger A, Wieder HA, Graf N et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med 2011;52:690-6.
116. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 200;32:663-71.
117. Choi SJ, Kim JS, Kim JH, Oh SJ, Lee JG, Kim CJ et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005;32:653-9.
118. Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005;46:1948-58. (Pubitemid 46657440)
119. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 2005;46:945-52. (Pubitemid 43733508)
120. Muzi M, Spence AM, O'Sullivan F, Mankoff DA, Wells JM, Grierson JR et al. Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas. J Nucl Med 2006;47:1612-21. (Pubitemid 47545026)
121. Yamamoto Y, Wong TZ, Turkington TG, Hawk TC, Reardon DA, Coleman RE. 3′-Deoxy-3′-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol 2006;8:340-7. (Pubitemid 44741371)
122. Saga T, Kawashima H, Araki N, Takahashi JA, Nakashima Y, Higashi T et al. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med 2006;31:774-80. (Pubitemid 44789556)
123. Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC 18F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging 2007;34:1003-11. (Pubitemid 46919556)
124. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25:4714-21. (Pubitemid 350086472)
125. Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K et al. Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 2008;14:2049-55. (Pubitemid 351551115)
126. Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T et al. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 2008;35:2009-17.
127. Price SJ, Fryer TD, Cleij MC, Dean AF, Joseph J, Salvador R et al. Imaging regional variation of cellular proliferation in gliomas using 3′-deoxy-3′-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study. Clin Radiol 2009;64:52-63.
128. Spence AM, Muzi M, Link JM, O'Sullivan F, Eary JF, Hoffman JM et al. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3′-deoxy-3′-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol 2009;11:343-55.
129. Backes H, Ullrich R, Neumaier B, Kracht L, Wienhard K, Jacobs AH. Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. Eur J Nucl Med Mol Imaging 2009;36:1960-7.
130. Barwick T, Bencherif B, Mountz JM, Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun 2009;30:908-17.
131. Tripathi M, Sharma R, D'Souza M, Jaimini A, Panwar P, Varshney R et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med 2009;34:878-83.
132. Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME et al. Kinetics of 3′-deoxy-3′-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med 2010;51:720-7.
133. Gilles R, Vogel WV, Gidding CE, Janssens GO, van der Vliet TM, Oyen WJ. (18)F-fluoro-L-thymidine-PET for the evaluation of primary brain tumours in children: a report of three cases. Nucl Med Commun 2010;31:482-7.
134. Hong IK, Kim JH, Ra YS, Kwon do H, Oh SJ, Kim JS. Diagnostic usefulness of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography in recurrent brain tumor. J Comput Assist Tomogr 2011;35:679-84.
135. Ullrich RT, Kracht LW, Jacobs AH. Neuroimaging in patients with gliomas. Semin Neurol 2008;28:484-94.
136. Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 2008;14:3416-26.
137. Muzi M, Spence AM, O'Sullivan F, Mankoff D, Wells JM, Grierson JR et al. Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas. J Nucl Med 2006;47:1612-21. (Pubitemid 47545026)
138. van Waarde A, Elsinga PH. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des 2008;14:3326-39.
139. Ishiwata K, Ido T, Kawashima K, Murakami M, Takahashi T. Studies on 18F-labeled pyrimidines. II. Metabolic investigation of 18F-5-fluorouracil, 18F-5-fluoro-2′-deoxyuridine and 18F-5-fluorouridine in rats. Eur J Nucl Med 1984;9:185-9. (Pubitemid 14144520)
140. Ishiwata K, Ido T, Takahashi T, Monma M, Iwata R, Abe Y et al. Syntheses of 18F-labeled pyrimidines and their usefulness for tumor imaging. Nucleic Acids Symp Ser 1984;15:25-8.
141. Tsurumi Y, Kameyama M, Ishiwata K, Katakura R, Monma M, Ido T et al. 18F-fluoro-2′-deoxyuridine as a tracer of nucleic acid metabolism in brain tumors. J Neurosurg 1990;72:110-3. (Pubitemid 20027307)
142. Ishiwata K, Sato K, Kameyama M, Yoshimoto T, Ido T. Metabolic fates of 2′-deoxy-5-[18F]fluorouridine in tumor-bearing mice and human plasma. Int J Rad Appl Instrum B 1991;18:539-45.
143. Ishiwata K, Takahashi T, Iwata R, Tomura M, Tada M, Itoh J et al. Tumor diagnosis by PET: potential of seven tracers examined in five experimental tumors including an artificial metastasis model. Int J Rad Appl Instrum B 1992;19:611-8.
144. Ishiwata K, Tsurumi Y, Kameyama M, Sato K, Iwata R, Takahashi T et al. Brain tumor accumulation and plasma pharmacokinetic parameters of 2′-deoxy-5-18F-fluorouridine. Ann Nucl Med 1993;7:199-205. (Pubitemid 23308863)
145. Sato K, Kameyama M, Ishiwata K, Kayama T, Yoshimoto T, Ito M. Multicentric glioma studied with positron emission tomography: a case report. Surg Neurol 1994;42:14-8. (Pubitemid 24273787)
146. Kameyama M, Ishiwata K, Tsurumi Y, Itoh J, Sato K, Katakura R et al. Clinical application of 18F-FUdR in glioma patients - PET study of nucleic acid metabolism. J Neurooncol 1995;23:53-61.
147. Tjuvajev JG, Macapinlac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD et al. Imaging of brain tumor proliferative activity with iodine-131- iododeoxyuridine. J Nucl Med 1994;35:1407-17. (Pubitemid 24280444)
148. Blasberg RG, R Wang H, Oliver P, Nan L, Wang S, Wang Z et al. Radiolabeled 2′-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2′-fluoro-5-methyldeoxyuracil-beta-D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemother Pharmacol 2002;49:419-24.
149. Conti PS, Bading JR, Mouton PP, Links JM, Alauddin MM, Fissekis JD et al. In vivo measurement of cell proliferation in canine brain tumor using C-11-labeled FMAU and PET. Nucl Med Biol 2008;35:131-41. (Pubitemid 350298247)
150. Blasberg RG, Roelcke U, Weinreich R, Beattie B, von Ammon K, Yonekawa Y et al. Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res 2000;60:624-35. (Pubitemid 30094560)
151. Gudjonssona O, Bergström M, Kristjansson S, Wu F, Nyberg G, Fasth KJ et al. Analysis of 76Br-BrdU in DNA of brain tumors after a PET study does not support its use as a proliferation marker. Nucl Med Biol 2001;28:59-65. (Pubitemid 32155965)
152. Roelcke U, Hausmann O, Merlo A, Missimer J, Maguire RP, Freitag P et al. PET imaging drug distribution after intratumoral injection: the case for (124)I-iododeoxyuridine in malignant gliomas. J Nucl Med 2002;43:1444-51. (Pubitemid 35285868)
153. Tehrani OS, Muzik O, Heilbrun LK, Douglas KA, Lawhorn-Crews JM, Sun H et al. Tumor imaging using 1-(2′-deoxy-2′-18F-fluoro-beta-D- arabinofuranosyl) thymine and PET. J Nucl Med 2007;48:1436-41. (Pubitemid 47397393)
154. Li HF, Winkeler A, Moharram S, Knaus EE, Dittmar K, Stöckle M et al. In vivo evaluation of the uptake of [(123)I]FIAU, [(123) I]IVFRU and [(123)I]IVFAU by normal mouse brain: potential for noninvasive assessment of HSV-1 thymidine kinase gene expression in gliomas. Nucleosides Nucleotides Nucleic Acids 2008;27:57-66.
155. Chopra A. Methyl-[11C]-4′-thiothymidine. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2011 2011 Aug 01
156. Sun H, Sloan A, Mangner TJ, Vaishampayan U, Muzik O, Collins JM et al. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging 2005;32:15-22. (Pubitemid 40142774)
157. Toyohara J, Nariai T, Sakata M, Oda K, Ishii K, Kawabe T et al. Whole-body distribution and brain tumor imaging with (11)C-4DST: a pilot study. J Nucl Med 2011;52:1322-8.
158. Alger JR, Frank JA, Bizzi A, Fulham MJ, DeSouza BX, Duhaney MO et al. Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 1990;177:633-41.
159. Luyten PR, Marien AJ, Heindel W, van Gerwen PH, Herholz K, den Hollander JA et al. Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. Radiology 1990;176:791-9. (Pubitemid 20266774)
160. Segebarth CM, Balériaux DF, Luyten PR, den Hollander JA. Detection of metabolic heterogeneity of human intracranial tumors in vivo by 1H NMR spectroscopic imaging. Magn Reson Med 1990;13:62-76. (Pubitemid 20084544)
161. Sutton LN, Wang Z, Gusnard D, Lange B, Perilongo G, Bogdan AR et al. Proton magnetic resonance spectroscopy of pediatric brain tumors. Neurosurgery 1992;31:195-202.
162. Fulham MJ, Bizzi A, Dietz MJ, Shih HH, Raman R, Sobering GS et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992;185:675-86.
163. Friedland RP, Mathis CA, Budinger TF, Moyer BR, Rosen M. Labeled choline and phosphorylcholine: body distribution and brain autoradiography: concise communication. J Nucl Med 1983;24:812-5. (Pubitemid 14234683)
164. Rosen MA, Jones RM, Yano Y, Budinger TF. Carbon-11 choline: synthesis, purification, and brain uptake inhibition by 2-dimethylaminoethanol. J Nucl Med 1985;26:1424-8. (Pubitemid 16063025)
165. Tan H, Chen L, Guan Y, Lin X. Comparison of MRI, F-18 FDG, and 11C-choline PET/CT for their potentials in differentiating brain tumor recurrence from brain tumor necrosis following radiotherapy. Clin Nucl Med 2011;36:978-81.
166. Rottenburger C, Hentschel M, Kelly T, Trippel M, Brink I, Reithmeier T et al. Comparison of C-11 methionine and C-11 choline for PET imaging of brain metastases: a prospective pilot study. Clin Nucl Med 2011;36:639-642.
167. Fallanca F, Giovacchini G, Picchio M, Bettinardi V, Messa C, Fazio F. Incidental detection by [11C]choline PET/CT of meningiomas in prostate cancer patients. Q J Nucl Med Mol Imaging 2009;53:417-21.
168. Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H et al. Metabolic assessment of gliomas using 11C-methionine, [18F]fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 2008;29:1176-82. (Pubitemid 351954890)
169. Huang Z, Zuo C, Guan Y, Zhang Z, Liu P, Xue F et al. Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours. Nucl Med Commun 2008;29:354-8. (Pubitemid 351644384)
170. Tian M, Zhang H, Higuchi T, Oriuchi N, Endo K. Oncological diagnosis using (11)C-choline-positron emission tomography in comparison with 2-deoxy-2-[(18)F]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol 2004;6:172-9. (Pubitemid 38771980)
171. Tian M, Zhang H, Oriuchi N, Higuchi T, Endo K. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging 2004;31:1064-72 (Pubitemid 39050172)
172. Utriainen M, Komu M, Vuorinen V, Lehikoinen P, Sonninen P, Kurki T et al. Evaluation of brain tumor metabolism with [11C] choline PET and 1H-MRS. J Neurooncol 2003;62:329-38. (Pubitemid 36591970)
173. Hara T, Kondo T, Hara T, Kosaka N. Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg 2003:99:474-9. (Pubitemid 37040406)
174. Ohtani T, Kurihara H, Ishiuchi S, Saito N, Oriuchi N, Inoue T et al. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med 2001;28:1664-70. (Pubitemid 33036109)
175. Hara T, Kosaka N, Shinoura N, Kondo T. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 1997;38:842-7. (Pubitemid 27251970)
176. Shinoura N, Nishijima M, Hara T, Haisa T, Yamamoto H, Fujii K et al. Brain tumors: detection with C-11 choline PET. Radiology 1997;202:497-503. (Pubitemid 27051749)
177. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805-14. (Pubitemid 34016349)
178. Kwee SA, Coel MN, Lim J, Ko JP. Combined use of F-18 fluorocholine positron emission tomography and magnetic resonance spectroscopy for brain tumor evaluation. J Neuroimaging 2004;14:285-359.
179. Spaeth N, Wyss MT, Pahnke J, Biollaz G, Lutz A, Goepfert K et al. Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L: -tyrosine and 18F-fluoro-2- deoxyglucose in F98 gliomas in the rat. Eur J Nucl Med Mol Imaging 2006;33:673-82. (Pubitemid 43846758)
180. Kwee SA, Ko JP, Jiang CS, Watters MR, Coel MN. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology 2007;244:557-65. (Pubitemid 47080889)
181. Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I. PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging 2010;37:2188-93.
182. Lam WW, Ng DC, Wong WY, Ong SC, Yu SW, See SJ. Promising role of [18F]fluorocholine PET/CT vs [18F]fluorodeoxyglucose PET/CT in primary brain tumors-early experience. Clin Neurol Neurosurg 2011;113:156-61.
183. Wyss MT, Spaeth N, Bioliaz G, Pahnke J, Alessi P, Trachsel E et al. Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis. J Nucl Med 2007;48:608-14. (Pubitemid 47571418)
184. Vanpouille C, Le Jeune N, Kryza D, Clotagatide A, Janier M, Dubois F et al. Influence of multidrug resistance on (18)F-FCH cellular uptake in a glioblastoma model. Eur J Nucl Med Mol Imaging 2009;36:1256-64.
185. Utriainen M, Komu M, Vuorinen V, Lehikoinen P, Sonninen P, Kurki T et al. Evaluation of brain tumor metabolism with [11C] choline PET and 1H-MRS. J Neurooncol 2003;62:329-38. (Pubitemid 36591970)
186. van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med 2006;47:150-4. (Pubitemid 46768524)
187. Huang Z, Zuo C, Guan Y, Zhang Z, Liu P, Xue F et al. Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours. Nucl Med Commun 2008;29:354-8. (Pubitemid 351644384)
188. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990-5. (Pubitemid 28270113)
189. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med, 2000;27:1415-9.
190. Mathews D, Oz OK. Positron emission tomography in prostate and renal cell carcinoma. Curr Opin Urol, 2002;12:381-5.
191. Bouchelouche K, Capala J, Oehr P. Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer. Curr Opin Oncol 2009;21:469-74.
192. Brown MA, Myears DW, Bergmann SR. Validity of estimates of myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography despite altered patterns of substrate utilization. J Nucl Med 1989;30:187-93. (Pubitemid 19048513)
193. Buxton DB, Schwaiger M, Nguyen A, Phelps ME, Scheiben HR. Radiolabeled acetate as a tracer of myocardial tricarboxylic acid cycle flux. Circ Res 1988;63:628-34.
194. Armbrecht JJ, Buxton DB, Brunken RC, Phelps ME, Schelbert HR. Regional myocardial oxygen consumption determined noninvasively in humans with [1-11C]acetate and dynamic positron tomography. Circulation 1989;80:863-72. (Pubitemid 19261634)
195. Henes CG, Bergmann SR, Walsh MN, Sobel BE, Geltman EM. Assessment of myocardial oxidative metabolic reserve with positron emission tomography and carbon-11 acetate. J Nucl Med 1989;30:1489-99. (Pubitemid 19231116)
196. Sciacca RR, Akinboboye O, Chou RL, Epstein S, Bergmann SR. Measurement of myocardial blood flow with PET using 1-11C-acetate. J Nucl Med 2001;42:63-70. (Pubitemid 32104779)
197. Shreve PD, Gross MD. Imaging of the pancreas and related diseases with PET carbon-11-acetate. J Nucl Med 1997;38:1305-10. (Pubitemid 27332636)
198. Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging 2009;36:422-7.
199. Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, et al 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43:181-6. (Pubitemid 34151040)
200. Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB et al. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med 2011;36:192-8.
201. Sun A, Johansson S, Turesson I, Daşu A, Sörensen J. Imaging Tumor Perfusion and Oxidative Metabolism in Patients with Head-and-neck Cancer using 1-[(11)C]-acetate PET during Radiotherapy: Preliminary Results. Int J Radiat Oncol Biol Phys 2012;82:554-60.
202. Liu RS, Chang CP, Chu LS, Chu YK, Hsieh HJ, Chang CW et al. PET imaging of brain astrocytoma with 1-11C-acetate. Eur J Nucl Med Mol Imaging 2006;33:420-7.
203. Tsuchida T, Takeuchi H, Okazawa H, Tsujikawa T, Fujibayashi Y. Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET. Nucl Med Biol 2008;35:171-6. (Pubitemid 351200042)
204. Yamamoto Y, Nishiyama Y, Kimura N, Kameyama R, Kawai N, Hatakeyama T, et al 11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET. Mol Imaging Biol 2008;10:281-7.
205. Lee SM, Kim TS, Kim SK. Cerebellopontine angle schwannoma on C-11 acetate PET/CT. Clin Nucl Med 2009;34:831-3.
206. Liu RS, Chang CP, Guo WY, Pan DH, Ho DM, Chang CW et al. 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery. J Nucl Med 2010;51:883-91.
207. Jonson SD, Welch MJ. Investigations into tumor accumulation and peroxisome proliferator activated receptor binding by F-18 and C-11 fatty acids. Nucl Med Biol 2002;29:211-6. (Pubitemid 34127954)
208. Marik J, Ogasawara A, Martin-McNulty B, Ross J, Flores JE, Gill HS et al. PET of glial metabolism using 2-18F-fluoroacetate. J Nucl Med 2009;50:982-90.
209. Ponde DE, Dence CS, Oyama N, Kim J, Tai YC, Uforest R et al. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging - in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med 2007;48:420-8. (Pubitemid 47604928)
210. Ho CL, Cheung MK, Chen S, To Cheung T, Lung Leung Y, Chau Cheng K et al. [(18)F]fluoroacetate Positron Emission Tomography for Hepatocellular Carcinoma and Metastases: An Alternative Tracer for [(11)C]Acetate? Mol Imaging [In press]2012.
211. Cai W, Guzman R, Hsu AR, Wang H, Chen K, Sun G et al. Positron emission tomography imaging of poststroke angiogenesis. Stroke 2009;40:270-7.
212. Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S et al. et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med 2007;48:445-54. (Pubitemid 47604931)
213. Cai W, Zhang X, Wu Y, Chen X. A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido) ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med 2006;47:1172-80. (Pubitemid 47544912)
214. Chen K, Cai W, Li ZB, Wang H, Chen X. Quantitative PET imaging of VEGF receptor expression. Mol Imaging Biol 2009;11:15-22.
215. Nagengast WB, Lub-de Hooge MN, Oosting SF, den Dunnen WF, Warnders FJ, Brouwers AH et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res 2011;71:143-53.
216. Wang H, Cai W, Chen K, Li ZB, Kashefi A, He L et al. A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging 2007;34:2001-10. (Pubitemid 350212131)
217. Wang JQ, Gao M, Miller KD, Sledge GW, Zheng QH. Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 2006;16:4102-6. (Pubitemid 44425196)
218. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F]Galacto-RGD positron emission tomography. Neuro Oncol 2009;11:861-70.
219. Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F- fluoromisonidazole and 150-H20. J Nucl Med 2004;45:1851-9-
220. Jerabek PA, Patrick TB, Kilbourn MR, Dischino DD, Welch MJ. Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. Int J Rad Appl Instrum A 1986;37:599-605. (Pubitemid 17190784)
221. Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiât Res 1987;111:292-304. (Pubitemid 17156952)
222. Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985-91. (Pubitemid 19279502)
223. Casciari JJ, Rasey JS. Determination of the radiobiologically hypoxic fraction in multicellular spheroids from data on the uptake of [3H]fluoromisonidazole. Radiat Res 1995;141:28-36.
224. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133-7.
225. Rasey JS, Casciari JJ, Hofstrand PD, Muzi M, Graham MM, Chin LK. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat Res 2000;153:84-92. (Pubitemid 30117087)
226. Tochon-Danguy HJ, Sachinidis JI, Chan F, Chan JG, Hall C, Cher L et al. Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl Med Biol 2002;29:191-7. (Pubitemid 34127952)
227. Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006;47:410-8. (Pubitemid 46768482)
228. Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HL, Muzi M et al. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med 2009;50:36-44.
229. Szeto MD, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord EC Jr et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res 2009;69:4502-9.
230. Huchet A, Fernandez P, Allard M, Belkacémi Y, Maire JP, Trouette R et al. Cancer Radiother. [Molecular imaging of tumor hypoxia]2009;13:747-57.
231. Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 2008;14:2623-30.
232. Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging 2003;30:259-66. (Pubitemid 36686845)
233. Komar G, Seppänen M, Eskola O, Lindholm P, Grönroos TJ, Forsback S et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008;49:1944-51.
234. Mahy P, Geets X, Lonneux M, Levêque P, Christian N, De Bast M et al. Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. Eur J Nucl Med Mol Imaging 2008;35:1282-9.
235. Shibahara I, Kumabe T, Kanamori M, Saito R, Sonoda Y, Watanabe M et al. Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-(18F]fluoro-1-[hydroxymethyl]ethoxy) methyl-2- nitroimidazole, a new 18F-labeled 2-nitroimidazole analog. J Neurosurg 2010;113:358-68.
236. Koch CJ, Scheuermann JS, Divgi C, Judy KD, Kachur AV, Freifelder R et al. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging 2010;37:2048-59.
237. Velikyan I, Sundberg AL, Lindhe O, Höglund AU, Eriksson O, Werner E et al. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 2005;46:1881-8. (Pubitemid 46196651)
238. Pal A, Glekas A, Doubrovin M, Balatoni J, Namavari M, Beresten T et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006;8:262-77. (Pubitemid 44446020)
239. Abourbeh G, Dissoki S, Jacobson O, Litchi A, Ben Daniel R, Laki D et al. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol 2007;34:55-70. (Pubitemid 46038157)
240. Wang H, Yu JM, Yang GR, Song XR, Sun XR, Zhao SQ et al. Further characterization of the epidermal growth factor receptor ligand 11C-PD153035. Chin Med J (Engl) 2007;120:960-4. (Pubitemid 46902174)
241. Lee FT, O'Keefe GJ, Gan HK, Mountain AJ, Jones GR, Saunder TH et al. Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806. J Nucl Med 2010;51:967-72.
242. Pal A, Glekas A, Doubrovin M, Balatoni J, Namavari M, Beresten T et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006;8:262-77. (Pubitemid 44446020)
243. Wang JQ, Gao M, Miller KD, Sledge GW, Zheng QH. Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 2006;16:4102-6. (Pubitemid 44425196)
244. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007;34:850-8. (Pubitemid 46798960)
245. Weber B, Winterdahl M, Memon A, Sorensen BS, Keiding S, Sorensen L et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 2011;6:1287-9.
246. Denholt CL, Binderup T, Stockhausen MT, Poulsen HS, Spang-Thomsen M, Hansen PR et al. Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. Nucl Med Biol 2011;38:509-15.
247. Muhr C, Bergström M, Lundberg PO, Bergström K, Hartvig P, Lundqvist H et al. Dopamine receptors in pituitary adenomas: PET visualization with 11C-N-methylspiperone. J Comput Assist Tomogr 1986;10:175-80. (Pubitemid 16113391)
248. Muhr C, Bergström M, Lundberg PO, Bergström K, Långström B. In vivo measurement of dopamine receptors in pituitary adenomas using positron emission tomography. Acta Radiol Suppl 1986;369:406-8.
249. Muhr C. Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology 2006;83:205-10. (Pubitemid 44578873)
250. Cascini GL, Ciarmiello A, Labate A, Tamburrini S, Quattrone A. Unexpected detection of melanoma brain metastasis by PET with iodine-124 betaCIT. Clin Nucl Med 2009;34:698-9.
251. Richardson MP, Hammers A, Brooks DJ, Duncan JS. Benzodiazepine-GABA(A) receptor binding is very low in dysembryoplastic neuroepithelial tumor: a PET study. Epilepsia 2001;42:1327-34. (Pubitemid 33070673)
252. Mäcke HR, Smith-Jones P, Maina T, Stolz B, Albert R, Bruns C et al. New octreotide derivatives for in vivo targeting of somatostatin receptor-positive tumors for single photon emission computed tomography (SPECT) and positron emission tomography (PET). Horm Metab Res Suppl 1993;27:12-7. (Pubitemid 23132613)
253. Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phel-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 2001;42:1053-6. (Pubitemid 32595304)
254. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 2005;46:763-9.
255. 3) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results. Clin Nucl Med 2011;36:101-8.
256. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapère JJ, Lindemann P et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006;27:402-9. (Pubitemid 44069585)
257. Veenman L, Papadopoulos V, Gavish M. Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr Pharm Des 2007;13:2385-405. (Pubitemid 47321571)
258. Veenman L, Shandalov Y, Gavish M. VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis. J Bioenerg Biomembr 2008;40:199-205.
259. Venturini I, Zeneroli ML, Corsi L, Avallone R, Farina F, Alho H et al. Up-regulation of peripheral benzodiazepine receptor system in hepatocellular carcinoma. Life Sci 1998;63:1269-80. (Pubitemid 29369143)
260. Giusti L, Costa B, Viacava P, Castagna M, Iacconi P, Ricci RE et al. Peripheral type benzodiazepine receptor in human parathyroid glands: up-regulation in adenoma. J Endocrinol Invest 2004;27:826-31. (Pubitemid 40305512)
261. Maaser K, Grabowski P, Oezdem Y, Krahn A, Heine B, Stein H et al. Up-regulation of the peripheral benzodiazepine receptor during human colorectal carcinogenesis and tumor spread. Clin Cancer Res 2005;11:1751-6. (Pubitemid 40471836)
262. Vlodavsky E, Soustiel JF. Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival. J Neurooncol 2007;81:1-7 (Pubitemid 44963983)
263. Königsrainer I, Vogel UF, Beckert S, Sotlar K, Coerper S, Braun A et al. Increased translocator protein (TSPO) mRNA levels in colon but not in rectum carcinoma. Eur Surg Res 2007;39:359-63. (Pubitemid 47614360)
264. Rechichi M, Salvetti A, Chelli B, Costa B, Da Pozzo E, Spinetti F et al. TSPO over-expression increases motility, transmigration and proliferation properties of C6 rat glioma cells. Biochim Biophys Acta 2008;1782:118-25.
265. Wang M, Gao M, Hutchins GD, Zheng QH. Synthesis of [11C] FEDAA1106 as a new PET imaging probe of peripheral benzodiazepine receptor expression. Eur J Med Chem 2009;44:2748-53.
266. Buck JR, McKinley ET, Hight MR, Fu A, Tang D, Smith RA et al. Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline. J Nucl Med 2011;52:107-14.
267. Takaya S, Hashikawa K, Turkheimer FE, Mottram N, Deprez M, Ishizu K et al. The lack of expression of the peripheral benzodiazepine receptor characterises microglial response in anaplastic astrocytomas. J Neurooncol 2007;85:95-103. (Pubitemid 47422662)
268. Hyun SH, Choi JY, Lee KH, Choe YS, Kim BT. Incidental focal 18F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria. J Nucl Med 2011;52:547-50.
269. Lee JW, Kang KW, Park SH, Lee SM, Paeng JC, Chung JK et al. 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging 2009;36:1574-82.
270. McCarthy M, Yuan JB, Campbell A, Lenzo NP, Butler-Henderson K 18F-fluorodeoxyglucose positron emission tomography imaging in brain tumours: the Western Australia positron emission tomography/cyclotron service experience. J Med Imaging Radiat Oncol 2008;52:564-9-
271. Estrada G, González-Maya L, Celis-López MA, Gavito J, Lárraga-Gutiérrez JM et al. Diagnostic approach in suspected recurrent primary brain tumors using (18)FDG-PET/MRI, perfusion MRI, Visual and quantitative analysis, and three dimensional stereotactic surface projections. First experience in Mexico. Rev Esp Med Nucl 2008;27:329-39.
272. Santra A, Kumar R, Sharma P, Bal C, Julka PK, Malhotra A. Detection of recurrence in glioma: a comparative prospective study between Tc-99m GHA SPECT and F-18 FDG PET/CT. Clin Nucl Med 2011;36:650-5.
273. Santra A, Kumar R, Sharma P, Bal C, Kumar A, Julka PK et al. F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. J Nucl Med 2000;41:1861-71.
274. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. Int J Cancer 2001;96:191-7.
275. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2011;81:1049-58.
276. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F et al. An interindividual comparison of O-(2-[18F] fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients, with brain gliomas and metastases. Eur J Nucl Med Mol Imaging 2010;37:685-90.
277. Yamane T, Sakamoto S, Senda M. Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm. J Nucl Med 2009;50:1962-8.
278. Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Neuroradiol 2010;37:89-97.
279. Dandois V, Rommel D, Renard L, Jamart J, Cosnard G. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: preliminary results in clinical practice. J Nucl Med 2008;49:694-9.
280. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. Clin Cancer Res 2004;10:7163-7170.
281. Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. J Neurosurg 2003;98:1056-64.
282. Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? Int J Radiat Oncol Biol Phys 2011;81:1049-58.
283. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F et al. An interindividual comparison of O-(2-[18F] fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Clin Nucl Med 2011;36:841-7.
284. Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Int J Radiat Oncol Biol Phys 2011;81:1049-58.
285. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F et al. An interindividual comparison of O-(2-[18F] fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Clin Neurol Neurosurg 2011;113:541-7.
286. Ewelt C, Floeth FW, Felsberg J, Steiger HJ, Sabel M, Langen KJ et al. Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence. Bull Cancer 2010;97:495-506.
287. Nataf V, Kerrou K, Balogova S, Pene F, Huchet V, Gutman F et al. Fluoroethylthyrosine 18F PET in the detection of brain tumours. J Nucl Med 2006;47:393-403.
288. Pöpperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? Eur J Nucl Med Mol Imaging 2010;37:1521-8.
289. Pichler R, Dunzinger A, Wurm G, Pichler J, Weis S, Nussbaumer K et al. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? J Clin Neurosci 2010;17:43-9.
290. Lau EW, Drummond KJ, Ware RE, Drummond E, Hogg A, Ryan G et al. Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci 2010;17:43-9.
291. Price SJ, Fryer TD, Cleij MC, Dean AF, Joseph J, Salvador R et al. Imaging regional variation of cellular proliferation in gliomas using 3′-deoxy-3′-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study. Clin Radiol 2009;64:52-63-
292. Choi SJ, Kim JS, Kim JH, Oh SJ, Lee JG, Kim CJ et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005,32:653-659.
293. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med 2010;51:1532-8.
294. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, et al 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006;47:904-11. (Pubitemid 46939941)
295. Tan H, Chen L, Guan Y, Lin X. Comparison of MRI, F-18 FDG, and 11C-choline PET/CT for their potentials in differentiating brain tumor recurrence from brain tumor necrosis following radiotherapy. Clin Nucl Med 2011;36:978-81.
296. Tan H, Chen L, Guan Y, Un X. Comparison of MRI, F-18 FDG, and 11C-choline PET/CT for their potentials in differentiating brain tumor recurrence from brain tumor necrosis following radiotherapy. Clin Nucl Med 2011;36:978-81.
297. Borbély K, Nyáry I, Tóth M, Ericson K, Gulyás B. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci 2006;246:85-94. (Pubitemid 43815341)